A theranostic SPECT probe for the treatment of PSMA-positive prostate cancer was reported by Jiao et al. 168 who hybridized the PSMA specific RNA aptamer A10-3.2 to MDM2 siRNA and functionalized it with the chelator SHNH for labeling with 99mTc 168. Here, FOLH1 is linked to prostate carcinoma.